Who is Lucy Guo? The tech star who just surpassed Taylor Swift on the billionaire list
Lucy Guo, 30, has just earned a new title, the youngest self-made female billionaire in the world, according to Forbes. With an estimated net worth of $1.3 billion, largely fuelled by her early stake in Scale AI, Guo now sits among the world's most powerful and intriguing tech entrepreneurs.
Her 5% stake in Scale AI, which she co-founded in 2016, is now valued at around $1.2 billion. Though she exited the company just two years after its founding, her role in shaping its early growth and operations has left a lasting imprint.
A childhood filled with codes for Lucy Guo
Born in Fremont, California, to Chinese immigrant parents, Guo started coding by the time she was in second grade. Encouraged by her own curiosity, even when her parents hesitated about her entering the male-dominated tech industry, she was creating bots for online games and earning real money before most kids knew what programming was.
She enrolled in Carnegie Mellon for computer science but left in 2014 after receiving the prestigious $100,000 Thiel Fellowship, which supports young entrepreneurs in building businesses instead of completing university.
From scale AI to startup stardom
After stints at Facebook, Snapchat, and Quora, Guo co-founded Scale AI alongside Alexandr Wang. She led operations and product design, while Wang served as CEO. Though creative and business differences led her to leave in 2018, her retained equity has since made her a billionaire.
Post-Scale, she launched Backend Capital and later founded Passes, a content platform positioned as a more family-friendly alternative to sites like OnlyFans. In 2024, Passes raised $40 million in Series A funding.
Facing challenges amid success
In early 2025, Passes became the subject of a class action lawsuit alleging the platform failed to prevent harmful content. Guo, named in the suit, denied any wrongdoing and described the case as a defamatory attempt to extort money from her and the company.
Guo splits her time between Los Angeles and Miami. Known for commuting by electric skateboard and collecting Pokémon cards, she balances her intense work ethic with an unapologetically bold lifestyle. While she acknowledges that her online presence can appear abrasive, those close to her say it is part of a confident, no-nonsense personality.
Currently ranked No. 26 on Forbes' Richest Self-Made Women list, just five spots behind Taylor Swift, Guo's story is proof that innovation, resilience, and vision can redefine the rules of tech and business.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
an hour ago
- Mint
Centre to introduce minimum import price on pharmaceutical raw materials to curb cheap Chinese imports
New Delhi: India plans to introduce a minimum import price (MIP) for select pharmaceutical raw materials in a move to shield its domestic industry from a flood of cheap Chinese imports, two people directly involved in the process said, a step that will also shore up India's status as the world's largest supplier of generic drugs. India accounts for about 20% of the global supply of generic drugs and manufactures about 60,000 generic brands, across 60 categories. The plan comes against the backdrop of the Centre's move to bulk up its Production Linked incentive (PLI) scheme for generic drugs by including more molecules used in manufacturing key starting materials (KSMs), drug intermediates, and Active Pharmaceutical Ingredients (APIs). KSMs and intermediates are chemical compounds used to synthesize APIs, which are the main components of a drug. 'The government is working on a plan to impose a minimum import price on all PLI based pharmaceutical products. The plan is to protect the domestic industry so that they are able to continue to do the business and to make India self-reliant," said one of the two people mentioned above. The measure seeks to build on India's recent success with domestic production of critical antibiotics such as Penicillin G. The API industry is a crucial segment of the pharmaceutical sector, accounting for about 35% of the market. However, India is dependent on imports for 80% of its bulk drug requirement. Bolstering self reliance The move also aims to bolster India's goal of self-reliance in the pharmaceutical sector. The heavy reliance on China, the world's largest producer and exporter of APIs, creates significant risks for India's medicine supply chain. In 2021, the government launched the ₹15,000 crore PLI scheme for the pharmaceuticals sector. There are about 500 API manufacturers in India, which account for about 8% of the global API industry. In addition, the production of APIs for essential medicines is also promoted through a dedicated PLI scheme for bulk drugs, KSMs and APIs. The government is seeking new applications as the previous iteration of the PLI scheme failed to meet the expectations due to dumping of cheap commodities from China. Also read | India curbs exports of 13 key pharma ingredients These schemes are aimed at protecting and encouraging domestic ingredient manufacturing which is seen as a critical step in securing the future growth and stability of India's pharma sector. According to the second person, the plan is a direct response to appeals from the domestic API industry, which has struggled to compete with the low prices of Chinese products. 'Actually, industry needs protection like some anti-dumping measures and MIP to make India self-reliant," the second person said, referring to a practice where a country 'dumps' its exports in other countries at prices that are less that what it costs to make these goods. Exports marginally higher As per commerce ministry data, India recorded a modest trade surplus in bulk drugs and intermediates in FY25, with exports totalling $4.90 billion and imports at $4.64 billion. In FY24, exports stood at $4.79 billion, slightly ahead of imports worth $4.56 billion, again resulting in a surplus. Similarly, in FY23, exports were $4.77 billion compared to imports of $4.51 billion, continuing the trend of a positive trade balance in this segment. The Indian Drugs Manufacturers' Association (IDMA) called for a cautious and data-driven approach to the proposal for imposing minimum import prices on select APIs and KSMs. The industry body has warned the government against a blanket application of the trade measure. 'We believe that a data-backed, well-studied and balanced approach should be considered," said Viranchi Shah, national spokesperson for IDMA. While the move is intended to discourage cheap imports and support the domestic pharma industry, Shah cautioned that India's strong position in finished formulation exports must not be compromised. Also read | India seeks financial details of pharmaceutical marketing practices 'The minimum import price should not come as a blanket strategy across the board, considering that India also has a very strong formulation industry," he said. 'Our industry has to remain competitive both domestically and globally." IDMA reiterated its support to the government's self-reliance push under the 'Atma-Nirbhar Bharat" campaign but urged policy planners to ensure that trade interventions like MIP do not end up hampering Indian exports by making them more costly. Queries sent to the spokespersons of India's commerce ministry, and department of pharmaceuticals on Friday and the Embassy of China in New Delhi on Saturday remained unanswered till the press time. China dependent Ajay Srivastava, co-founder of the Global Trade Research Initiative (GTRI), a policy think tank, said India's chemicals and pharmaceuticals sector—which plays a crucial role in healthcare, agriculture, and industry—is becoming heavily dependent on imports from China. 'This growing reliance not only exposes India to supply chain vulnerabilities but also raises significant strategic concerns, especially in the current global climate where geopolitical tensions and trade disruptions are increasingly common. Strengthening domestic production is thus not just an economic priority but a national security imperative," he said. A GTRI report from April 2024 states that India's imports of chemicals and pharmaceuticals reached $54.8 billion in FY2024. Between 2007 and 2022, China's share in these imports rose sharply from 18% to 29%, with imports from China increasing nearly fourfold—from $4.4 billion to $17.4 billion. Also read | Bitter pill for Indian pharma as Trump tariffs could hurt exports by $2.25 bn Although imports from other countries has also ballooned, the heavy dependence on China remains a major strategic concern. In 2022, India's chemical and pharmaceutical imports totaled $76.94 billion, with China accounting for 26.8%, followed by Saudi Arabia, the US, Japan, and Russia. There has been a notable increase in antibiotic imports from $551.2 million in 2007-10 to $1.27 billion in 2020-22, an increase of 130.7%. Here too, China's market share climbed to 81.7%, underscoring a high dependency on Chinese pharmaceutical products essential for addressing widespread public health needs in India, it said. Instrument of control A minimum import price is an instrument used by countries to control surplus imports. As a case in point, India has used MIPs to curb the import of steel and agricultural products like onions and pulses. By filtering out extremely low-cost imports, MIP also helps maintain quality standards, ensuring that only manufacturers capable of meeting cost-based compliance and quality norms supply APIs to the Indian market. 'While such a measure could lead to a short-term increase in input costs for drug makers dependent on Chinese supplies, it is seen as a necessary step for strengthening the domestic pharmaceutical ecosystem and reducing strategic vulnerabilities," said Abhash Kumar, a trade economist and assistant professor of economics at Delhi University. Also read | India eyes Asean to boost pharma exports An MIP is not outright banned under WTO rules, but it can face challenges if used unfairly or for extended periods. The WTO also allows rules-based instruments like tariffs or anti-dumping duties backed by formal investigations. India imposed an MIP on steel in 2016, but later replaced it with WTO-compliant remedies like safeguard duties.
Time of India
an hour ago
- Time of India
Auto companies seek govt help for magnet imports
NEW DELHI: The automobile industry has sought govt support in expediting approvals from the Chinese govt for importing rare earth magnets used in various applications, including passenger cars. As per sources, various domestic suppliers have already sought approval from the Chinese govt through their local vendors in China. However, no approvals have been granted so far, sources said. China controls over 90% of global processing capacity for the magnets, used across multiple sectors including automobiles, home appliances and clean energy. The Chinese govt has put restrictions, with effect from April 4, mandating special export licences for seven rare earth elements. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Mint
3 hours ago
- Mint
BYD Unleashes an EV Industry Reckoning That Alarms Beijing
(Bloomberg) -- The price war engulfing China's electric vehicle industry has sent share prices tumbling and prompted an unusual level of intervention from Beijing. The shakeout may just be getting started. For all the Chinese government's efforts to prevent price cuts by market leader BYD Co. from turning into a vicious spiral, analysts say a combination of weaker demand and extreme overcapacity will slice into profits at the strongest brands and force feebler competitors to fold. Even after the number of EV makers starting shrinking for the first time last year, the industry is still using less than half its production capacity. Chinese authorities are trying to minimize the fallout, chiding the sector for 'rat race competition' and summoning heads of major brands to Beijing last week. Yet previous attempts to intervene have had little success. For the short term at least, investors are betting few automakers will escape unscathed: BYD, arguably the biggest winner from industry consolidation, has lost $21.5 billion in market value since its shares peaked in late May. 'What you're seeing in China is disturbing, because there's a lack of demand and extreme price cutting,' said John Murphy, a senior automotive analyst at Bank of America Corp. Eventually there will be 'massive consolidation' to soak up the excess capacity, Murphy said. For automakers, relentless discounting erodes profit margins, undermines brand value and forces even well-capitalized companies into unsustainable financial positions. Low-priced and low-quality products can seriously damage the international reputation of 'Made-in-China' cars, the People's Daily, an outlet controlled by the Communist Party, said. And that knock would come just as models from BYD to Geely, Zeekr and Xpeng start to collect accolades on the world stage. For consumers, price drops may seem beneficial but they mask deeper risks. Unpredictable pricing discourages long-term trust — already people are complaining on China's social media, wondering why they should buy a car now when it may be cheaper next week — while there's a chance automakers, as they cut costs to stay afloat, may reduce investment in quality, safety and after-sales service. Auto CEOs were told last week they must 'self-regulate' and shouldn't sell cars below cost or offer unreasonable price cuts, according to people familiar with the matter. The issue of zero-mileage cars also came up — where vehicles with no distance on their odometers are sold by dealers into the second-hand market, seen widely as a way for automakers to artificially inflate sales and clear inventory. Chinese automakers have been discounting a lot more aggressively than their foreign counterparts. Murphy said US automakers should just get out. 'Tesla probably needs to be there to compete with those companies and understand what's going on, but there's a lot of risk there for them.' Others leave no room for doubt that BYD, China's No. 1 selling car brand, is the culprit. 'It's obvious to everyone that the biggest player is doing this,' Jochen Siebert, managing director at auto consultancy JSC Automotive, said. 'They want a monopoly where everybody else gives up.' BYD's aggressive tactics are raising concerns over the potential dumping of cars, dealership management issues and 'squeezing out suppliers,' he said. The pricing turmoil is also unfolding against a backdrop of significant overcapacity. The average production utilization rate in China's automotive industry was mere 49.5% in 2024, data compiled by Shanghai-based Gasgoo Automotive Research Institute show. An April report by AlixPartners meanwhile highlights the intense competition that's starting to emerge among new energy vehicle makers, or companies that produce pure battery cars and plug-in hybrids. In 2024, the market saw its first ever consolidation among NEV-dedicated brands, with 16 exiting and 13 launching. 'The Chinese automotive market, despite its substantial scale, is growing at a slower speed. Automakers have to put top priority now on grabbing more market share,' Ron Zheng, a partner at global consultancy Roland Berger GmbH, said. Jiyue Auto shows how quickly things can change. A little over a year after launching its first car, the automaker jointly backed by big names Zhejiang Geely Holding Group Co. and technology giant Baidu Inc., began to scale down production and seek fresh funds. It's a dilemma for all carmakers, but especially smaller ones. 'If you don't follow suit once a leading company makes a price move, you might lose the chance to stay at the table,' AlixPartners consultant Zhang Yichao said. He added that China's low capacity utilization rate, which is 'fundamentally fueling' the competition, is now even under more pressure from export uncertainties. While the push to find an outlet for excess production is thrusting more Chinese brands to export, international markets can only offer some relief. 'The US market is completely closed and Japan and Korea may close very soon if they see an invasion of Chinese carmakers,' Siebert said. 'Russia, which was the biggest export market last year, is now becoming very difficult. I also don't see Southeast Asia as an opportunity anymore.' The pressure of cost cutting has also led analysts to express concern over supply chain finance risks. A price cut demand by BYD to one of its suppliers late last year attracted scrutiny around how the car giant may be using supply chain financing to mask its ballooning debt. A report by accounting consultancy GMT Research put BYD's true net debt at closer to 323 billion yuan ($45 billion), compared with the 27.7 billion yuan officially on its books as of the end of June 2024. The pain is also bleeding into China's dealdership network. Dealership groups in two provinces have gone out of business since April, both of them ones that were selling BYD cars. Beijing's meeting with automakers last week wasn't the first attempt at a ceasefire. Two years ago, in mid 2023, 16 major automakers, including Tesla Inc., BYD and Geely signed a pact, witnessed by the China Association of Automobile Manufacturers, to avoid 'abnormal pricing.' Within days though, CAAM deleted one of the four commitments, saying that a reference to pricing in the pledge was inappropriate and in breach of a principle enshrined in the nation's antitrust laws. The discounting continued unabated. --With assistance from Yasufumi Saito and Chester Dawson. More stories like this are available on
